Format

Send to

Choose Destination
Mol Imaging Biol. 2016 Aug;18(4):617-26. doi: 10.1007/s11307-015-0916-7.

Multimodal In Vivo Imaging of Tumorigenesis and Response to Chemotherapy in a Transgenic Mouse Model of Mammary Cancer.

Author information

1
CEA, DSV, I2BM, Service Hospitalier Frédéric Joliot, Laboratoire d'Imagerie Moléculaire Expérimentale, Orsay, France.
2
Service de Médecine nucléaire, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France.
3
Faculté de Médecine, Université Versailles Saint-Quentin, Versailles, France.
4
Service de pharmacologie, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France.
5
Service de pathologie, Institut Curie, Hôpital René Huguenin, Saint-Cloud, France.
6
Université Paris Descartes Sorbonne Paris Cité, Assistance Publique-Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Radiology Department, Paris, France. bertrand.tavitian@inserm.fr.
7
Université Paris Descartes Sorbonne Paris Cité, INSERM UMR 970, Cardiovascular Research Center - PARCC, 56 rue Leblanc, 75015, Paris, France. bertrand.tavitian@inserm.fr.

Abstract

PURPOSE:

Transgenic mice expressing the polyoma middle T oncoprotein (PyMT) in the mammary epithelium were explored by multimodal imaging to monitor longitudinally spontaneous tumor growth and response to chemotherapy.

PROCEDURES:

Positron emission tomography (PET) with 2-deoxy-2-[(18)F]fluoro-D-glucose ([(18)F]FDG) and 3'-deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT), single photon emission tomography (SPECT) with [(99m)Tc]TcO4 ([(99m)Tc]TEC), X-ray computed tomography, and fluorescent confocal endomicroscopy (FCE) images were acquired during tumor progression in female PyMT mice. Imaging with [(18)F]FDG and [(99m)Tc]TEC was also performed in untreated, doxorubicin-treated, and docetaxel-treated PyMT mice. Total tumor volumes were quantified. Tumors were collected and macroscopic and histological examinations were performed.

RESULTS:

All PyMT mice developed multifocal tumors of the mammary epithelium that became palpable at 8 weeks of age (W8). Computed tomography (CT) detected tumors at W14, while a clear tumoral uptake of [(99m)Tc]TEC and [(18)F]FDG was present as early as W6 and W8, respectively. No contrast between mammary tumors and surrounding tissue was observed at any stage with [(18)F]FLT. FCE detected an angiogenic switch at W10. Lung metastases were not clearly evidenced by imaging. Doxorubicin and docetaxel treatments delayed tumor growth, as shown by [(18)F]FDG and [(99m)Tc]TEC, but tumor growth resumed upon treatment discontinuation. Tumor growth fitted an exponential model with time constant rates of 0.315, 0.145, and 0.212 week(-1) in untreated, doxorubicin, and docetaxel groups, respectively.

CONCLUSIONS:

Molecular imaging of mammary tumors in PyMT is precocious, precise, and predictive. [(18)F]FDG-PET and [(99m)Tc]TEC SPECT monitor tumor response to chemotherapy.

KEYWORDS:

Biomarker; Breast cancer; Molecular imaging; Response to treatment; Sodium-iodide symporter; Transgenic model

PMID:
26630973
PMCID:
PMC4927598
DOI:
10.1007/s11307-015-0916-7
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center